Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Lifecore Biomedical, Inc. \De\ (LFCR) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Lifecore Biomedical, Inc. \De\ (LFCR) over the last 17 years, with Q2 2025 value amounting to 14.62%.

  • Lifecore Biomedical, Inc. \De\'s EBITDA Margin rose 89400.0% to 14.62% in Q2 2025 from the same period last year, while for May 2025 it was 13.38%, marking a year-over-year decrease of 299500.0%. This contributed to the annual value of 13.38% for FY2025, which is 64900.0% down from last year.
  • Per Lifecore Biomedical, Inc. \De\'s latest filing, its EBITDA Margin stood at 14.62% for Q2 2025, which was up 89400.0% from 25.68% recorded in Q1 2025.
  • Lifecore Biomedical, Inc. \De\'s 5-year EBITDA Margin high stood at 47.16% for Q4 2023, and its period low was 137.58% during Q1 2023.
  • Moreover, its 5-year median value for EBITDA Margin was 15.32% (2023), whereas its average is 18.58%.
  • Its EBITDA Margin has fluctuated over the past 5 years, first crashed by -1102200bps in 2023, then surged by 1813600bps in 2024.
  • Over the past 5 years, Lifecore Biomedical, Inc. \De\'s EBITDA Margin (Quarter) stood at 14.41% in 2021, then plummeted by -497bps to 57.26% in 2022, then surged by 182bps to 47.16% in 2023, then tumbled by -113bps to 6.02% in 2024, then soared by 343bps to 14.62% in 2025.
  • Its EBITDA Margin stands at 14.62% for Q2 2025, versus 25.68% for Q1 2025 and 6.02% for Q4 2024.